Patents Assigned to Centre National da la Recherche Scientifique
  • Patent number: 6979540
    Abstract: This invention concerns the use, for synthesizing and immobilising nucleic acids, of a solid support modified by an organized self-assembled monolayer of one or several organosilicon compounds. The invention also concerns methods for synthesizing and immobilizing nucleic acids on such a silanized solid support, and DNA chips obtained by said methods.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: December 27, 2005
    Assignee: Centre National da la Recherche Scientifique
    Inventors: Bernard Benneteau, Jamal Bousbaa, Franck Choplin, Eliane Souteyrand, Jean-René Martin, Jean-Pierre Cloarec
  • Publication number: 20030036528
    Abstract: Compounds and pharmaceutical compositions active against HIV are provided, as is a method for the treatment of HIV infection in humans and other host animals is provided comprising administering an effective amount of a &bgr;-L-(2′ or 3′-azido)-2′,3′-dideoxy-5-fluorocytosine of the formula 1
    Type: Application
    Filed: June 18, 2002
    Publication date: February 20, 2003
    Applicant: The Centre National da la Recherche Scientifique
    Inventors: Gilles Gosselin, Jean-Louis Imbach, Jean-Pierre Sommadossi, Raymond F. Schinazi
  • Patent number: 6444652
    Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: September 3, 2002
    Assignees: Novirio Pharmaceuticals Limited, Centre National da la Recherche Scientifique
    Inventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant
  • Patent number: 6395716
    Abstract: This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-&bgr;-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: May 28, 2002
    Assignees: Novirio Pharmaceuticals Limited, Centre National da la Recherche Scientifique
    Inventors: Gilles Gosselin, Jean-Louis Imbach, Martin L. Bryant